Amgen’s Aranesp v. Procrit Promotional Claims Result In Off-Label Guilty Plea

Amgen pled guilty to marketing Aranesp off-label as part of a global settlement with the government; the final agreement, expected to be approved on Dec. 19, could involve marketing practices of Enbrel and six other drugs.